TY - JOUR T1 - Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo JF - Archives of disease in childhood - Education & practice edition JO - Arch Dis Child Educ Pract Ed SP - ep124 LP - ep124 VL - 91 IS - 4 A2 - , Y1 - 2006/12/01 UR - http://ep.bmj.com/content/91/4/ep124.abstract N2 - Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 2005;116:1289–95.OpenUrlCrossRefPubMedWeb of Science In patients with acute, uncomplicated rhinosinusitis lasting ⩾7 days, what is the relative effectiveness of mometasone furoate nasal spray, amoxicillin, and placebo? Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Allergy & immunology ★★★★★☆☆ Respirology ★★★★★☆☆ Design: randomised controlled trial. Allocation: unclear allocation concealment.* Blinding: blinded (patients and healthcare providers).* Follow up period: up to 29 days. Setting: 71 medical centres in 14 countries. Patients: 981 patients ⩾12 years of age (mean age 35 y, 66% women) with signs and symptoms of acute rhinosinusitis for ⩾7 days but ⩽28 days and major symptom score (MSS) ⩾5 but ⩽12, with ⩽3 of 5 symptoms rated as severe (based on the sum of scores for rhinorrhoea, postnasal drip, nasal congestion/stuffiness, sinus headache, and facial pain/pressure/tenderness). Intervention: mometasone furoate nasal spray, 200 μg, once daily for 15 days (n  =  243); mometasone spray, 200 μg, twice daily for 15 days (n  =  235); amoxicillin, 500 mg, … ER -